Head & Neck Cancer Therapeutics Market Size & Share 2024 to 2032

Head & Neck Cancer Therapeutics Market Size

Head & Neck Cancer Therapeutics Market size was valued at USD 1.8 billion in 2023 and is set to register growth at a CAGR of 8.9% from 2024 and 2032. The growth of this market is primarily driven by the increasing prevalence of head and neck cancer.

According to statistics published by GLOBOCAN, head and neck cancer is one of the most common cancers globally. Additionally, the growing consumption of tobacco and alcohol, which are major risk factors for head and neck cancers, will further drive industry growth.
 

Another significant growth driver is the expanding geriatric population base, which is more susceptible to various chronic conditions, thereby elevating market demand. As people age, the likelihood of genetic mutations increases, and the body's ability to repair damaged DNA decreases, leading to a higher risk of cancer. This natural aging process suggests that a larger elderly population will likely result in a higher number of cancer cases. According to the American Cancer Society, about 57% of new cancer cases and 75% of cancer deaths occur in people aged 65 and older. This age group is the fastest-growing segment of the population, particularly in developed countries like the U.S.
 

Head and neck cancer is defined as a group of cancers that develop in the throat, mouth, nose, larynx, sinuses, or salivary glands. These cancers are typically categorized by the specific area they affect, such as oral, laryngeal, or pharyngeal cancer. The majority of these cancers are referred to as squamous cell carcinomas, as they originate from squamous cells that line the moist surfaces inside the head and neck.
 

Head & Neck Cancer Therapeutics Market Trends

• The increasing prevalence of head and neck cancer is a significant driver of the market.
   
• For instance, according to the National Cancer Institute, 71,000 people in the U.S. will suffer from pharynx, larynx, or oral cancer in 2024.
   
• HPV, particularly HPV type 16, is a significant risk factor for oropharyngeal cancers, especially those affecting the tonsils and the base of the tongue. The increasing prevalence of HPV-related infections has been linked to a rise in these types of cancers. HPV-positive head and neck cancers tend to affect younger individuals who might not have traditional risk factors like smoking or alcohol use.
   
• As the incidence of HPV rises globally, there is a growing demand for effective treatments to alleviate symptoms and improve patients' quality of life. This trend is boosting the expansion of the head & neck cancer market.
   
• Additionally, ongoing research and development efforts to enhance the efficacy and safety of head & neck cancer drugs further bolster market growth, meeting the increasing therapeutic needs of a larger patient population.
   

Head & Neck Cancer Therapeutics Market Analysis

Based on therapy type, the market is segmented into chemotherapy, immunotherapy, targeted therapy, and other therapies. The immunotherapy segment dominated the market in 2023 and accounted for USD 972.7 million.
 

• Immunotherapy is considered as a promising treatment option for head and neck cancers, particularly for patients with advanced or recurrent disease. This approach leverages the body’s immune system to recognize and attack cancer cells, offering an alternative to traditional therapies like surgery, radiation, and chemotherapy.
   
• Pembrolizumab is approved as a first line of treatment for patients suffering with metastatic or recurrent head and neck squamous cell carcinoma (HNSCC). This therapy is either given alone or in combination with chemotherapy and has witnessed positive outcomes in recent times.
   
• Moreover, ongoing development of new formulations further boost its market share.

Learn more about the key segments shaping this market

Download Free PDF

Based on route of administration, the head & neck cancer therapeutics market is bifurcated into injectable, oral and other routes of administration. The injectable segment dominated the market in 2023 with a market share of 57.4%.
 

• Several leading immunotherapy drugs for head and neck cancer, such as Pembrolizumab (Keytruda) and Nivolumab (Opdivo), are administered as IV injectables. These drugs target specific proteins on cancer cells or immune cells, requiring direct administration into the bloodstream to be effective.
   
• Additionally, injectables allow for precise control over dosage and administration, which is essential in cancer treatment to maximize efficacy while minimizing side effects. This precision is particularly important in head and neck cancers, where the proximity of vital structures like the airway and nerves requires careful management, thereby increasing the adoption rate of injectables.
   
• The development of new injectable therapies, including targeted agents and immunotherapies, is a major focus in oncology research. These advances are driving the preference for injectables as they offer novel and effective treatment options for head and neck cancer.
   

Based on distribution channel, the head & neck cancer therapeutics market is segmented into hospital, retail & specialty, and online pharmacy. The retail & specialty pharmacy segment dominated the market in 2023 and is expected to witness growth at a CAGR of 8.6%.
 

• Retail & specialty pharmacies hold a high market share in the market due to the convenience and accessibility they offer to cancer patients who may have limited mobility or live far from treatment centers. These pharmacy outlets are widely available.
   
• Currently, most of the retail and specialty pharmacies offer home delivery services, ensuring that patients can receive their medications without the need to travel. This service is especially beneficial for those undergoing intensive treatments or dealing with side effects, further enhancing the preference for this segment.
   
• Moreover, retail and specialty pharmacies, especially in developed countries, offer programs designed to improve medication adherence, such as refill reminders, counselling, and follow-up calls. Ensuring that patients take their medications as prescribed is critical for the effectiveness of cancer therapies.

North America dominated the global head & neck cancer therapeutics market in 2023 with a revenue of USD 661.4 million and is anticipated to reach USD 1.4 billion by 2032.
 

• This regional dominance stems from a robust healthcare system and established regulatory pathways that expedite the market entry and adoption of novel therapies.
   
• Moreover, heightened patient awareness and access to innovative treatment options solidify North America's leading stance in the global head and neck cancer therapeutics arena.
   
• North America has been a pioneer in embracing treatment modalities like immunotherapy and targeted therapy. Notably, drugs such as Pembrolizumab (Keytruda) and Nivolumab (Opdivo), now standard for advanced head and neck cancers, saw their initial approval and widespread use in the U.S.
   

In 2023, the U.S. head & neck cancer therapeutics market was valued at USD 609.2 million.
 

• As the world's largest and most advanced market for head and neck cancer therapeutics, the U.S. benefits from a confluence of factors: a high disease prevalence, vigorous research and development, swift adoption of groundbreaking treatments, and a formidable healthcare infrastructure.
   
• Moreover, the rising incidence of HPV-related oropharyngeal cancers, among the most prevalent head and neck cancers, has broadened the patient base seeking specialized therapies.
   
• Comprehensive insurance coverage enables patients to access high-cost therapies, thereby boosting the demand for these therapeutics.
   

Germany is poised for significant growth in the global head & neck cancer therapeutics market.
 

• With its citizens enjoying comprehensive healthcare coverage, Germany ensures access to a broad spectrum of cancer treatments, including innovative head and neck cancer therapeutics. This universal access propels the demand for these treatments.
   
• The German government's substantial investment in medical research, particularly cancer research, nurtures innovation in head and neck cancer therapies, paving the way for new drugs and treatment protocols.
   
• Germany's growing focus on personalized medicine, tailoring treatments to the unique genetic and molecular profiles of patients’ tumors, is especially pertinent in head and neck cancers, where such therapies can markedly enhance outcomes.
   

The Asia Pacific region is set to experience robust growth in the head & neck cancer therapeutics market, projected at a CAGR of 10.9% during the analysis period.
 

• Countries like China, with prevalent risk factors such as tobacco use, alcohol consumption, and betel nut chewing, face a significant burden of head and neck cancers.
   
• India's emergence as a medical tourism hub, drawing patients for affordable and high-quality cancer treatment, further fuels the demand for advanced cancer therapeutics.
   
• While some regions are still catching up with advanced therapies like immunotherapy and targeted therapy, markets like Japan, South Korea, and Australia are witnessing a surge in their adoption. As these therapies gain approvals and find their way into treatment protocols, their accessibility is set to rise, propelling regional market growth.
   

Head & Neck Cancer Therapeutics Market Share

The competitive landscape in the market is dynamic and highly competitive, driven by both established pharmaceutical giants and innovative biotechnology firms. Major players, such as Elli Lilly and Company, Sanofi dominate the market due to their strong brand presence and focus on developing novel immunotherapies and targeted therapies, which have become the standard of care in treating head and neck cancers. Their leadership is supported by successful clinical trials, regulatory approvals, and strong marketing strategies.
 

Head & Neck Cancer Therapeutics Market Companies

Prominent players operating in the head & neck cancer therapeutics industry include:

• AbbVie Inc.
• Amgen Inc.
• AstraZeneca plc
• Bristol-Myers Squibb Company (BMS)
• C.H. Boehringer Sohn AG & Co. KG
• Clinigen Group plc.
• Coherus BioSciences
• Cumberland Pharmaceuticals, Inc.
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• GSK plc
• Merck & Co., Inc.
• Sanofi S.A.
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd.
   

Head & Neck Cancer Therapeutics Industry News:

• In May 2023, Bristol-Myers Squibb Company entered a strategic partnership with The Swallows Head & Neck Cancer Support Charity to enhance treatment provided to patients suffering from cancer.
   

The head & neck cancer therapeutics market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Therapy Type

• Chemotherapy
• Immunotherapy
• Targeted therapy
• Other therapies  

Market, By Route of Administration

• Injectable
• Oral
• Other routes of administration

Market, By Distribution Channel

• Hospital pharmacy
• Retail & specialty pharmacy
• Online pharmacy

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada 
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa